Newest Filing: Immune Design Corp: Biotechnology Value Fund L P Opened Big New Position

Newest Filing: Immune Design Corp: Biotechnology Value Fund L P Opened Big New Position

The New Biotechnology Value Fund L P Holding in Immune Design Corp

Biotechnology Value Fund L P filed with the SEC SC 13G form for Immune Design Corp. The form can be accessed here: 000092189516006171. As reported in Biotechnology Value Fund L P’s form, the filler as of late owns 5.3% or 1,339,792 shares of the -company.

Immune Design Corp stake is a new one for the and it was filed because of activity on November 4, 2016. We feel this shows Biotechnology Value Fund L P’s positive view for the stock.

Immune Design Corp Institutional Sentiment

Latest Security and Exchange filings show 58 investors own Immune Design Corp. The institutional ownership in Q3 2015 is high, at 70.50% of the outstanding shares. This is increased by 4148462 the total institutional shares. 17913947 were the shares owned by these institutional investors. In total 3 funds opened new Immune Design Corp stakes, 25 increased stakes. There were 7 that closed positions and 18 reduced them.

2 managers had the stock in their top Ten. Notable investors are: Proquest Associates Iv Llc..

Stuart Weisbrod Iguana Healthcare Management Llc is an institutional investor bullish on Immune Design Corp, owning 75000 shares as of Q3 2015 for 0.36% of its portfolio. Cormorant Asset Management Llc owns 189000 shares or 0.37% of its portfolio. FL Proquest Associates Iv Llc have 5.67% of their stock portfolio for 1962720 shares. Further, Sectoral Asset Management Inc reported stake worth 0.47% of its US stock portfolio. The CA Column Group L P owns 3161942 shares. Immune Design Corp is 100.00% of the manager’s US portfolio.

Business Profile

Immune Design Corp. is a clinical stage immunotherapy company. The Company focuses on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. The Company is developing multiple product candidates from its discovery platforms, including ZVex and GLAAS. ZVex is a discovery platform that uses a vector to generate product candidates designed to create cytotoxic T cells (CTLs) in vivo. The ZVex vector is a delivery system based on a hybrid, re-engineered virus designed to carry the genetic information of selected tumor antigen in whole or selected epitopes selectively to dendritic cells (DCs) in the skin. When injected into a cancer patient, a ZVex-based product candidate is designed to interact only with these DCs, delivering the tumor antigen in the form of ribonucleic acid (RNA). GLA Adjuvant Systems (GLAAS) is a discovery platform that works in vivo and is based on a synthetic molecule called glucopyranosyl lipid A (GLA).

SEC Form 13G is required when the filer owns between (5% and 20%) of a company and plans to hold it only as a passive investor. In case the filler intend to exert control and the stake’s exceeds 20%, then 13D Form must be filed. These filings can NOT be a precursor to “change of control” events such as hostile takeovers, company breakups or others.

Insitutional Activity: The institutional sentiment increased to 1.25 in Q2 2016. Its up 0.21, from 1.04 in 2016Q1. The ratio increased, as 8 funds sold all Immune Design Corp shares owned while 16 reduced positions. 8 funds bought stakes while 22 increased positions. They now own 9.57 million shares or 12.34% less from 10.92 million shares in 2016Q1.

Great West Life Assurance Can has 9,836 shares for 0% of their US portfolio. Blackrock Fund Advisors holds 549,736 shares or 0% of its portfolio. Tfs Cap Limited Liability has 0.15% invested in the company for 102,685 shares. Point72 Asset Mngmt Limited Partnership has invested 0% of its portfolio in Immune Design Corp (NASDAQ:IMDZ). Walleye Trading Ltd Co has 0% invested in the company for 200 shares. Blackrock Advisors Limited Liability holds 0% of its portfolio in Immune Design Corp (NASDAQ:IMDZ) for 60,355 shares. Tiaa Cref Invest Ltd Liability last reported 43,523 shares in the company. Tower Rech Capital Limited Liability Corporation (Trc) last reported 0% of its portfolio in the stock. Blackrock Inv Mngmt Ltd Liability holds 0% or 41,876 shares in its portfolio. Morgan Stanley has invested 0% of its portfolio in Immune Design Corp (NASDAQ:IMDZ). Pictet Asset Ltd has 0.04% invested in the company for 748,145 shares. Retail Bank Of New York Mellon has invested 0% of its portfolio in Immune Design Corp (NASDAQ:IMDZ). Alps Inc holds 0% or 28,310 shares in its portfolio. Springbok Cap Mngmt Limited Liability Company reported 800 shares or 0% of all its holdings. Proshare Advsrs Lc last reported 16,372 shares in the company.

Insider Transactions: Since July 15, 2016, the stock had 4 insider purchases, and 0 insider sales for $10.26 million net activity. Shares for $10,255 were bought by Brady Stephen R on Friday, July 15. 800,000 shares were bought by Svennilson Peter, worth $5.00M. COLUMN GROUP L P bought 800,000 shares worth $5.00M. COLEMAN LEWIS W bought $250,000 worth of stock or 40,000 shares.

The stock decreased 1.20% or $0.1 during the last trading session, hitting $8.2. About 144,773 shares traded hands or 54.11% up from the average. Immune Design Corp (NASDAQ:IMDZ) has declined 40.71% since April 12, 2016 and is downtrending. It has underperformed by 45.70% the S&P500.

Immune Design Corp. is a clinical stage immunotherapy company. The company has a market cap of $205.98 million. The Firm focuses on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. It currently has negative earnings. The Firm is developing multiple product candidates from its discovery platforms, including ZVex and GLAAS.

Immune Design Corp (NASDAQ:IMDZ) Ratings Coverage

Out of 2 analysts covering Immune Design (NASDAQ:IMDZ), 2 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. $40 is the highest target while $17 is the lowest. The $28.50 average target is 247.56% above today’s ($8.2) stock price. Immune Design has been the topic of 4 analyst reports since August 18, 2015 according to StockzIntelligence Inc. The firm earned “Buy” rating on Wednesday, August 10 by Jefferies. As per Wednesday, September 9, the company rating was initiated by Jefferies. The firm has “Outperform” rating given on Tuesday, August 18 by Leerink Swann.

Another recent and important Immune Design Corp (NASDAQ:IMDZ) news was published by Quotes.Wsj.com which published an article titled: “News Immune Design Corp.IMDZ” on July 23, 2014.

According to Zacks Investment Research, “Immune Design Corp. is a clinical-stage immunotherapy company. The Company is focused on the development of immune-based therapies based on its DCVex (TM) and GLAAS (TM) discovery platforms for cancer and other chronic conditions. Its product candidates in Phase I clinical trials comprise LV305, CMB305, and G305 for the treatment of solid tumor types, such as breast cancer, melanoma, non-small cell lung cancer, ovarian cancer, or sarcoma; and G100 for the treatment of patients with merkel cell carcinoma. Immune Design Corp. is headquartered in Seattle, Washington.”

IMDZ Company Profile

Immune Design Corp., incorporated on February 20, 2008, is a clinical-stage immunotherapy company. The Firm focuses on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. The Firm is developing multiple product candidates from its discovery platforms, including ZVex and GLAAS. ZVex is a discovery platform that uses a vector to generate product candidates designed to create cytotoxic T cells (CTLs) in vivo. The ZVex vector is a delivery system based on a hybrid, re-engineered virus designed to carry the genetic information of selected tumor antigen in whole or selected epitopes selectively to dendritic cells (DCs) in the skin. When injected into a cancer patient, a ZVex product candidate is designed to interact only with these DCs, delivering the tumor antigen in the form of ribonucleic acid (RNA).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Related posts

Leave a Comment